CIOMS FORM

SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-06055

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year	Years		Day	Month	Year	
KXPF	NICARAGUA	28	Aug	2019	5	Female	29	May	2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Off-label use for non-approved indication (Off label use (10053762), Off label use (10053762)) (29/May/2025 -) - Unknown
2) Frequent mood swings (Mood swings (10027951), Mood swings (10027951)) (/Aug/2025 -) - Not Recovered/Not Resolved/Ongoing
3) High sensitivity to the environment (Ill-defined disorder (10061520), Ill-defined disorder (10061520)) (/Aug/2025 -) - Not Recovered/Not Resolved/Ongoing

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(15211CUY;UNK;UNK)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (29/May/2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1-9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-06055
24c. DATE RECEIVED BY MANUFACTURER: 21/Aug/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 25/Aug/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium (reference number: NI-ADIUM-NI-0071-20250821 (0)) via Patient Support Program on 21-Aug-2025 from a consumer (non-health care professional) regarding a child 05-year-old female patient who experienced non-serious events of "frequent mood swings" (Mood swings) "high sensitivity to the environment"(Ill-defined disorder) and "off-label use for non-approved indication"(Off label use) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 22-Aug-2025.

The patient's medical history was unknown and current condition included precocious puberty.

Concomitant medications were unknown.

On 29-May-2025, the patient began receiving Eligard 22.5 mg, every 3 months via subcutaneous route for precocious puberty (Lot numbers;15211CUY; UNK; UNK and Expiration dates May-2026; UNK; UNK).

On an unknown date, in Aug-2025, the patient had frequent mood swings and had high sensitivity to the environment. No further details were provided.

Corrective treatment was unknown.

Action taken with Eligard in response to the event was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of mood swings and Ill-defined disorder not recovered.

The outcome of off label use was unknown.

The reporter did not assess the seriousness of mood swings, Ill-defined disorder and off label use.

The reporter assessed the causality of mood swings and Ill-defined disorder in relationship to Eligard and Eligard Unspecified device as related.

The reporter did not provide the causality of off label use in relationship to Eligard and Eligard Unspecified device.

No further queries were raised.

Listedness:

Mood swings>Eligard>Unlisted as per CCDS>07-Nov-2024
Mood swings>Eligard>Unlisted as per USPI>Feb-2025
Mood swings>Eligard Unspecified device>Unlisted as per USPI>Feb-2025
Mood swings>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Ill-defined disorder>Eligard>Unlisted as per CCDS>07-Nov-2024
Ill-defined disorder>Eligard>Unlisted as per USPI>Feb-2025
Ill-defined disorder>Eligard Unspecified device>Unlisted as per USPI>Feb-2025
Ill-defined disorder>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Off label use>Eligard>Unlisted as per CCDS>07-Nov-2024
Off label use>Eligard>Unlisted as per USPI>Feb-2025
Off label use>Eligard Unspecified device>Unlisted as per USPI>Feb-2025
Off label use>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluators comments : As per company conventions, the events mood swings, Ill-defined disorder and off label use are considered with not applicable causality by default. The events are unlisted/unexpected with reference to the current CCDS/SmPC and as per company conventions. All the events are non-serious. The benefit-risk profile of Eligard (Drug and device) is not adversely affected by this report.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection

Continuation Sheet for CIOMS report

Lot Number	:	1) 15211CUY;UNK;UNK
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Therapy Dates	:	1) From : 29/May/2025 To :Continuing
Action(s) Taken With Drug	:	Dose not changed

Causality

1) Off-label use for non-approved indication (Off label use - 10053762, Off label use - 10053762)

Causality as per reporter	:	Not Reported
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) Frequent mood swings (Mood swings - 10027951, Mood swings - 10027951)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

3) High sensitivity to the environment (Ill-defined disorder - 10061520, Ill-defined disorder - 10061520)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) Off-label use for non-approved indication
CORE UnLabeled

2) Frequent mood swings
CORE UnLabeled

3) High sensitivity to the environment
CORE UnLabeled

2) Drug	:	Eligard® Unspecified Device (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) 15211CUY; UNK;UNK
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug	:	Not applicable

Causality

1) Off-label use for non-approved indication (Off label use - 10053762, Off label use - 10053762)

Causality as per reporter	:	Not Reported
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) Frequent mood swings (Mood swings - 10027951, Mood swings - 10027951)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

3) High sensitivity to the environment (Ill-defined disorder - 10061520, Ill-defined disorder - 10061520)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) Off-label use for non-approved indication
CORE

2) Frequent mood swings
CORE

3) High sensitivity to the environment
CORE